Napo Announces Successful Clinical Results In Phase 2 Study Of Crofelemer In Acute Adult Infectious Diarrhea
Apr 11th 2008Drug InformationGastroIntestinal / Gastroentorology
Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Glenmark Pharmaceuticals Limited (BSE: Glenmark).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
